Acalabrutinib manufacturer?

Acalabrutinib is manufactured by AbbVie Inc. [1]

Who is developing acalabrutinib?

Acalabrutinib was originally developed by Acerta Pharma, a company that was acquired by AstraZeneca in 2016. AstraZeneca's subsidiary, Hematologics, then advanced the drug. [2]

What is acalabrutinib used for?

Acalabrutinib, marketed as Calquence, is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor. It is used to treat adults with certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). [3]

When did acalabrutinib receive FDA approval?

The U.S. Food and Drug Administration (FDA) granted accelerated approval for acalabrutinib for MCL in October 2017 and for CLL/SLL in March 2019. [3]

What is the patent status for acalabrutinib?

Information regarding the patent status and expiration dates for acalabrutinib can be found on DrugPatentWatch.com. [4]